Ximelagatran: an oral direct thrombin inhibitor

The Annals of Pharmacotherapy
William E DagerEdith A Nutescu

Abstract

To present the chemistry, pharmacology, and pharmacokinetics of ximelagatran, an oral direct thrombin inhibitor (DTI), and to review available comparative clinical trial data evaluating its efficacy and safety relative to other antithrombotic agents in the prevention and treatment of thromboembolism. A search of the PubMed and Cochrane databases (1995-August 2004), supplemented by a manual search of article bibliographies, conference abstracts, and data on file from the manufacturer, was conducted. Key search terms were ximelagatran, melagatran, H376/95, and direct thrombin inhibitors. Pertinent information from available clinical trials, including study design, patient demographics, dosing regimens, anticoagulant comparators, methods for evaluating effectiveness, treatment outcomes, adverse events, and pharmacokinetic and pharmacodynamic evaluations, was extracted. Ximelagatran is an orally administered DTI under development for use in the treatment of venous thromboembolism (VTE), long-term prevention of a second VTE event, stroke secondary to atrial fibrillation, prevention of VTE after orthopedic procedures, and recurrent ischemic events after acute myocardial infarction. Ximelagatran, in twice-daily doses of 24 or 36 mg, i...Continue Reading

References

Jul 29, 1998·Archives of Internal Medicine·R H WhiteW Bargar
Nov 30, 1999·Annals of Internal Medicine·R G Hart, J L Halperin
Dec 11, 1999·JAMA : the Journal of the American Medical Association·S S Anand, S Yusuf
Feb 7, 2001·Chest·W H GeertsH B Wheeler
Feb 7, 2001·Chest·G W AlbersD E Singer
Mar 27, 2001·The Journal of Bone and Joint Surgery. American Volume·P C CompUNKNOWN Enoxaparin Clinical Trial Group
Apr 10, 2002·Pharmacotherapy·Simon de Denus, Sarah A Spinler
Jul 20, 2002·Lancet·Robert F van EsUNKNOWN Antithrombotics in the Secondary Preventionof Events in Coronary Thrombosis-2 (ASPECT-2) Research Group
Sep 27, 2002·The New England Journal of Medicine·Mette HurlenHarald Arnesen
Dec 6, 2002·The New England Journal of Medicine·D G WyseUNKNOWN Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators
Dec 6, 2002·The New England Journal of Medicine·Isabelle C Van GelderUNKNOWN Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group
Feb 14, 2003·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Ulf G ErikssonDavid Gustafsson
Feb 26, 2003·The New England Journal of Medicine·Paul M RidkerUNKNOWN PREVENT Investigators
Mar 28, 2003·American Heart Journal·Ewurabena SimpsonLouise Pilote
Apr 16, 2003·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Bernd Clement, Katrin Lopian
May 13, 2003·Expert Opinion on Pharmacotherapy·Karen L Kaplan
May 14, 2003·Journal of the American College of Cardiology·Palle PetersenUNKNOWN SPORTIF II Investigators
May 14, 2003·European Journal of Clinical Pharmacology·Ulf G ErikssonDavid Gustafsson
May 30, 2003·The Annals of Pharmacotherapy·William E Dager
Jun 5, 2003·Expert Opinion on Pharmacotherapy·William E Dager, Richard H White

❮ Previous
Next ❯

Citations

Sep 24, 2011·International Journal of Inflammation·Arthur J Chu
Jul 4, 2015·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Evangelia LiakoniStephan Krähenbühl
Nov 26, 2008·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Alejandro Lazo-LangnerPhilip S Wells
Feb 24, 2005·Journal of Cardiovascular Pharmacology·Spyros KokolisJonathan D Marmur
Jul 7, 2005·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Michael P Gulseth
Jun 11, 2005·Journal of Thrombosis and Haemostasis : JTH·Y Laurian
Aug 4, 2005·Expert Review of Cardiovascular Therapy·Christopher J Boos, Gregory Y H Lip
Oct 28, 2019·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Fabio AngeliGianpaolo Reboldi

❮ Previous
Next ❯

Methods Mentioned

BETA
total hip arthroplasty

Software Mentioned

Autoplex
THRIVE
ELATE
PREVENT

Related Concepts

Related Feeds

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Related Papers

JAMA : the Journal of the American Medical Association
Jean-Noel FiessingerTHRIVE Treatment Study Investigators
American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
Michael P Gulseth
Drug Safety : an International Journal of Medical Toxicology and Drug Experience
William M LeeSunita Sheth
© 2021 Meta ULC. All rights reserved